The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice given that it has shown improved overall survival in randomized clinical trials. Other immune modulating agents, such as programmed death receptor‐1 and programmed death receptor ligand‐1 antibodies, are showing promise in early clinical trials. This manuscript will review ipilimumab and its most common side effects. Immune‐related adverse events (irAEs) are important to recognize early, and their presentation, timing of onset, and general recommendations for workup and management will be reviewed. Assembling a multidisciplinary team, as well as thorough education of the patient, is recommended to optimize patient care. 摘要 过去的几年内，转移性黑色素瘤的治疗已出现的重大的进步。作为一种免疫疗法， ipilimumab已在随机临床试验中证实能够改善总生存，因而是目前肿瘤临床实践的主流。其他免疫调节剂，如程序化死亡受体1以及程序化死亡受体配体1抗体，也在早期临床试验中获得很有希望的结果。本文将回顾ipilimumab及其最常见的副反应。免疫相关不良事件（irAE）的早期识别是非常重要的，本文还将讨论irAE的临床表现、发作时间以及对检查和治疗管理的一般性建议。我们推荐建立多学科团队，同时对患者进行全面教育，这样才能获得最优化的患者管理。The Oncologist 2013;18:733‐743 Ipilimumab is now in mainstream oncology practice and it has shown improved overall survival in randomized clinical trials. Other immune modulating agents are showing promise in early clinical trials. This review discusses ipilimumab, its side effects, and their management.